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ABSTRACT: Calcitriol and its analogues are considered drugs supporting the anticancer treatment of breast 
cancer and preventing the osteoporosis that results from the development of cancer or from chemotherapy or 
hormone therapy. Following the orthotopic implantation of 4T1 mammary carcinoma cells into aged 
ovariectomized (OVX) mice, we evaluated the effects of calcitriol and its two analogues, PRI-2191 and PRI-2205, 
on metastatic spread and bone homeostasis. Calcitriol and its analogues temporarily inhibited the formation of 
metastases in the lungs. Unexpectedly, only mice treated with calcitriol analogues showed a deterioration of 
bone-related parameters, such as bone column density, marrow column density and the CaPO4 coefficient. These 
findings correlated with an increased number of active osteoclasts differentiated from bone marrow-derived 
macrophages in mice treated with the analogues. Interestingly, in the tumours from mice treated with PRI-2191 
and PRI-2205, the expression of Tnfsf11 (RANKL) was increased. On the other hand, osteopontin (OPN) levels 
in plasma and tumour tissue, as well as TRAC5b levels in tumours, were diminished by calcitriol and its 
analogues. Despite a similar action of both analogues towards bone metabolism, their impact on vitamin D 
metabolism differed. In particular, PRI-2191 and calcitriol, not PRI-2205 treatment significantly diminished the 
levels of both 25(OH)D3 and 24,25(OH)2D3. In conclusion, though there is evident antimetastatic activity in old 
OVX mice, signs of increased bone metabolism and deterioration of bone mineralization during therapy with 
calcitriol analogues were observed. 
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There is ample evidence that cancer is linked to the ageing 
process (e.g., reviewed in [1]). In animal studies, Meehan 
et al. have shown that ageing influences the metastatic 
phenotype of cancer cells. Indeed, lung metastases are less 
aggressive and smaller in old mice than in young mice [2]. 
Moreover, impairment of angiogenesis is described to be 
the cause of slower cancer growth in the elderly [3]. 
Further, tumour responsiveness to therapeutic agents 
differs in young and old animals [3,4]. Despite this 
evidence, the overwhelming majority of research focusing 
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on the antitumour activity of various compounds is carried 
out on young animals. 
Vitamin D deficit is ubiquitous and is more common 
and severe in the elderly [5]. In addition to the classical 
effects associated with vitamin D deficiency, the non-
classical ones are common, such as an increased risk of 
sepsis, cardiovascular and metabolic disorders (e.g., 
hyperlipidaemia, type 2 diabetes, dementia, stroke and 
heart failure) [6]. The hypovitaminosis D often correlates 
with an increased risk of breast cancer, its prognosis, and 
sensitivity to antineoplastic therapy [7,8]. Furthermore, 
cancer itself [9] and the applied therapeutic schemes that 
reduce oestrogens level (e.g., oophorectomy, chemo-
therapy, and aromatase inhibitors) enhance bone 
resorption without a compensatory increase in bone 
formation [10–13].  
1,25-Dihydroxyvitamin D3 (calcitriol), a hormonally 
active metabolite of vitamin D3, is the ligand for the 
nuclear vitamin D3 receptor (VDR). VDR is expressed and 
regulated in the mammary gland during the reproductive 
cycle [14]. Moreover, in VDR-knockout mice compared 
to wild-type mice, enhanced mammary gland 
development during puberty and early pregnancy, as well 
as weaker apoptosis during involution, were observed 
[14]. Further, chronic removal of VDR signalling during 
ageing revealed large effects on ovarian function and 
metabolism that are associated with mammary gland 
alterations, such as atrophy of the fat pad, epithelial ductal 
branching degeneration, extended lymph nodes and 
chronic inflammation [15]. Recently, Chen et al. reported 
that older mice (1 year old) develop different types of 
spontaneous tumours during vitamin D deficiency [16]. 
Moreover, the same authors have shown that vitamin D 
deficiency leads to increased oxidative stress and DNA 
damage, resulting in accelerated ageing and 
tumourigenesis through oncogene activation [16].  
Calcitriol and its analogues have been shown to 
influence the proliferation of stromal and epithelial 
mammary gland cells in vitro. Moreover, their inhibitory 
effect on the growth of different breast cancer cell lines 
has also been demonstrated [17–19]. Additionally, there 
are experimental animal studies suggesting the beneficial 
influence of vitamin D or its analogues on the growth of 
breast cancer xenografts [17,20,21] and transplantable 
mouse mammary gland tumours [22–24]. The animal 
studies also showed that vitamin D deficiency accelerated 
mammary gland tumour growth and metastasis [25,26]. 
On the other hand, our recent studies have shown that in 
the 4T1 mouse mammary gland cancer model 
transplanted orthotopically, the metastatic spread of 
cancer cells was accelerated upon treatment with calcitriol 
or its analogues in young 6- to 8-week-old mice [27,28]. 
Cao et al. also demonstrated enhanced 4T1 primary 
tumour growth in mice treated with vitamin D3 [29]. 
There are also randomized clinical trials showing that 
vitamin D supplementation does not significant effect 
against cancer [30]. Moreover, the clinical trials in which 
low calcaemic analogues of calcitriol are used in cancer 
patients as monotherapy do not prove its efficacy [31,32]. 
More benefits seem to result from the combined use of 
calcitriol or its analogues with other anticancer therapies 
(summarized in recent review [31]). For example, 
inecalcitol combined with docetaxel in prostate cancer 
[33], or with decitabine in acute lymphatic leukemia 
(AML) has been subjected to such clinical trials. 
Ultimately, inecalcitol was approved as an orphan drug in 
the treatment of AML [31]. The lack of benefits from 
vitamin D and its analogues in clinical trials is in contrast 
with the encouraging effects from preclinical studies and 
could be due to undefined bias in patient selection criteria 
or to the fact that preclinical studies were performed in 
inadequate experimental models (young animals only). 
The majority of breast cancer patients are over 40 
years old, and the survival outcomes of older and younger 
breast cancer patients are different [34]. Moreover, it has 
been postulated to supplement with vitamin D to avoid 
deficiency in breast cancer patients and in the elderly [35–
38]. The study presented here focuses on the assessment 
of the effect of vitamin D and its selected analogues on 
the growth and metastasis of 4T1 tumours in 60-week-old 
ovariectomized (OVX) mice.  
 
MATERIALS AND METHODS 
 
Compounds 
 
Calcitriol (1,25(OH)2D3) and its analogues PRI-2191 and 
PRI-2205 were obtained from the Pharmaceutical 
Research Institute, Warsaw, Poland. Samples of the 
compounds were stored in amber ampoules under argon 
at -20C. Compounds were dissolved in 99.8% ethanol 
and then diluted in 80% propylene glycol (PEG) to reach 
the required concentrations. All compounds were freshly 
prepared immediately before administration. Working 
solutions of macrophage colony-stimulating factor (M-
CSF; BioLegend, San Diego, USA) and receptor activator 
for nuclear factor κB (RANKL, R&D Systems, Inc., 
Minneapolis, USA) used in osteoclast formation were 
prepared and stored according to the manufacturer’s 
instructions. 
 
Cells and cell line culture 
 
Mouse mammary adenocarcinoma 4T1 cells were 
obtained from American Type Culture Collection (ATCC, 
Rockville, Maryland, USA). The cells were immediately 
used in experiments. The 4T1 cell line was maintained in 
a mixture of RPMI-1640 and Opti-MEM (1:1, Gibco, 
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Scotland, UK) adjusted to contain 3.5 g/l glucose, 2 mM 
L-glutamine and 0.5 mM sodium pyruvate (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany) with 5% 
foetal bovine serum (HyClone, GE Healthcare, UK). 
Culture medium was supplemented with 100 U/mL 
penicillin (Polfa Tarchomin S.A., Warsaw, Poland) and 
100 µg/ml streptomycin (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany). The cells were grown at 37°C in a 
humidified atmosphere with 5% CO2. 
 
Mouse studies 
 
Female BALB/c mice at 60 weeks old and weighing 24–
34 g were obtained from the Center of Experimental 
Medicine of the Medical University of Bialystok 
(Bialystok, Poland) and were maintained in specific 
pathogen-free conditions. All experiments were 
performed according to EU Directive 2010/63/EU on the 
protection of animals used for scientific purposes and 
were approved by the first Local Committee for 
Experiments with the Use of Laboratory Animals, 
Wroclaw, Poland (Permission No.: 40/2014 from July 16, 
2014).  
Ovariectomy (OVX) was performed under general 
anaesthesia. Mice received an intraperitoneal injection of 
buprenorphine at a dose of 0.2 mg/kg (VET-AGRO Sp. z 
o.o., Poland) and were anaesthetized with a mixture of 
synthetic air and isoflurane (4% for induction and 2-3% 
v/v for maintenance; 200 ml/min; Aerrane isofluranum, 
Baxter, Canada). After shaving, a 1-2 cm skin middle 
incision was made, the skin was gently separated, and two 
small incisions were made lateral to the midline. The 
ovaries were identified and cut, and the wounds were 
closed with soluble surgical sutures. Twenty-four hours 
after surgery and on subsequent days when signs of pain 
existed, buprenorphine (0.1 mg/kg) was injected. As 
controls, mice underwent the same surgical procedure 
without removing the ovaries (sham).  
Four weeks after OVX and sham operations, BALB/c 
mice received an orthotopic inoculation of 1104 viable 
4T1 breast cancer cells per mouse in 0.05 ml (45 μl of 
Hanks solution with 5 μl of Matrigel) into the right 
mammary fat pad and then were randomly divided into 
groups to receive treatment (7 mice per group). The day 
of tumour inoculation was labelled as day 0.  
Vitamin D analogues were administered 
subcutaneously (s.c.) thrice weekly starting from day 7 
after tumour cell inoculation. The single dose of 
compounds was as follows: calcitriol, 0.5 µg/kg; PRI-
2191, 1.0 µg/kg; and PRI-2205, 10.0 µg/kg (Fig. 1). The 
doses of compounds were selected during previous 
studies based on their toxicity and anticancer activity [39]. 
Control mice (both OVX and sham operated) were 
administered with vehicle (80% PEG) in the same volume 
and scheme as vitamin D compounds. Mice were 
euthanized as follows: (1) Sham operated: day 0 (before 
tumour cell transplantation); day 7 (before compound 
administration); and days 21 and 33; (2) OVX: day 0 
(before tumour cell transplantation); day 7 (before 
compound administration); and days 14, 21, 28 and 33. 
In the graphs, control mice (receiving the vehicle) are 
described as follows: "sham" - sham operated, tumour 
bearing mice; "control" - OVX, tumour bearing mice. Day 
0 means mice not inoculated with cancer cells, sham-
operated or OVX. 
 
 
 
 
Figure 1. Time course of experiment.  
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Blood and tumours were harvested on days 14, 21, 28, 
and 33 after the inoculation of 4T1 cells, and bone marrow 
cells were collected on day 28. Blood was also collected 
before tumour cell inoculation (day 0) and on day 7, 
before starting treatment. The mice were anaesthetized 
with a 3-5% (v/v) mixture of isoflurane (Aerrane 
isofluranum, Baxter, Canada) in synthetic air (200 
ml/min) prior to blood collection and sacrifice. The 
control group euthanized on day 7 was included to 
monitor the condition of the tumour-bearing mice at the 
beginning of the treatment. Some of the analyses were 
performed only on day 14 or 21 (early stages of tumour 
progression) and on day 28 or 33 (late stages of tumour 
progression) (Fig. 1). 
Radiographs of mouse bones were taken from old (60 
week) and young (6-8-week-old) BALB/c mice 
orthotopically inoculated with 4T1 breast cancer cells 
(1104 cells per mice) during the studies as described 
previously [27,28]. The protocol for young mice was also 
approved by the first Local Committee for Experiments 
with the Use of Laboratory Animals, Wroclaw, Poland 
(Permission no.: 40/2014 from July 16, 2014). 
Tumours were measured by using a calliper three 
times a week. Tumour volume was calculated using the 
formula (a2  b)/2, where a = shorter tumour diameter in 
mm and b = longer tumour diameter in mm. Mice were 
sacrificed when the tumour volume exceeded 2,000 mm3. 
Multiple tumours were not observed in our study. 
Metastases were counted in lungs fixed in 4% buffered 
formalin by two independent examiners. 
 
Evaluation of tumour angiogenesis 
 
To evaluate the influence of calcitriol and its analogues on 
tumour angiogenesis, tumour perfusion was evaluated on 
day 24 by ultrasound imaging, as previously described 
[27]. Briefly, ultrasound imaging was performed after 
MicroMarkerTM Contrast Agent (VisualSonics, Canada) 
intravenous injection in anaesthetized animals placed on 
the handling station. The central section of the tumour was 
visualized. Signal of the contrast marker accumulating in 
the tumour was recorded using the probe at 13–24 MHz 
frequency (MS250, VisualSonics, Canada). Next, the 
peak-enhancement [Contrast Mean Power as l.a.u.] 
parameter was calculated using Vevo LAB 1.7.1 Software 
(VisualSonics, Ontario, Canada). 
 
Bone homeostasis 
 
Calcium level was measured in each sample of plasma 
using the Cobas c 111 z ISE device (Roche Diagnostics 
Ltd., Rotkreuz, Switzerland). 
Radiographs of mouse bones were taken on day 28 
after the administration of anaesthesia on a Kodak/ 
Carestream FX PRO Imaging System for a total of 3-6 
young and old mice (for each group). Images were 
acquired using the X-ray source energy at 35 kVp with an 
X-ray calibrated energy of ~13 keV. Binning was set at 2 
X & 2 Y with a 0.4 mm aluminium filter, an ƒ-stop of 
5.57, an exposure time of 2 min, and FOV = 200, which 
provided sufficient grey scale values for acquiring an 
image quality suitable for bone mineral density 
measurements. Images were processed using Bruker 
Molecular Imaging software v.7.1.3.20550 with the 
Bruker Bone Density Software Module by quantifying 
pixels after selecting the femur regions of interest [40,41]. 
The analysis of the vitamin D metabolite profile 
(25(OH)D3, 25(OH)D2 and 24,25(OH)2D3) was 
performed with high-performance liquid chromatography 
coupled with mass spectrometry using an isotope dilution 
methodology. Whole blood was collected on Whatman 
903 cards and dried to obtain dried blood spots (DBS). 
Two 3 mm discs were cut out, pooled together and 
subjected for methanol extraction. Before analysis, 
vitamin D metabolites were derivatized with 4-(4'-
dimethyl-aminophenyl)-1,2,4-triazoline-3,5-dione (DAP 
TAD) [42]. Chromatographic separation (Exion LC, 
Sciex) was performed on a Kinetex 1.7 µm F5 100 Å, 50 
x 2.1 mm column in 8-min gradients of water and 
acetonitrile with 0.1% formic acid (0.45 mL/min; 40⁰C). 
Detection in MRM mode was done on a 4500QTRAP 
(Exion LC, Sciex) in electrospray positive ionization 
mode. The results were multiplied by haematocrit values 
to obtain vitamin D metabolite serum concentrations. 
 
Mouse T Helper Cell Differentiation RT2 Profiler Array 
 
Total RNA was isolated from tumour tissue using TRIzol 
(TRI Reagent; Sigma-Aldrich, Germany) according to the 
manufacturer’s procedure. The quantity of RNA was 
established using a NanoDrop 2000 at 260 nm (Thermo 
Fisher Scientific, Waltham, MA, USA). First-strand 
cDNA synthesis was performed using a compatible RT 
First Strand Kit (Qiagen, Hilden, Germany), eventually 
achieving 0.5 µg of cDNA (four mice pooled per group) 
for a single reaction. The Mouse T Helper Cell 
Differentiation RT2 Profiler Array was obtained from 
Qiagen Company (Qiagen, Hilden, Germany). This PCR 
array detects the expression of 84 key genes associated 
with differentiation of T cell precursors into specific 
effector subtypes and five housekeeping genes (list of 
genes included in Supplementary Table 1). Cycling 
conditions for PCR amplification were as follows: 95C 
for 10 min (1 cycle), followed by 40 cycles of 95C for 15 
s and 60C for 1 min. The expression of mRNA was 
measured by real-time PCR through a ViiA™ 7 Real-
Time PCR System (Thermo Fisher Scientific, USA) with 
SYBR green chemistry (Qiagen, Hilden, Germany). 
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Relative quantification (RQ) values of target genes was 
defined using ΔΔCt values with reference to the heat 
shock protein 90 alpha, class B member 1 (Hsp90ab1) 
gene. Data were analysed using Qiagen online software 
suitable for the purchased kit (Qiagen, Hilden, Germany). 
 
ELISA 
 
The expression of selected proteins was detected in mouse 
plasma and tumour homogenates. Blood specimens were 
collected during mice euthanasia. Next, blood was 
immediately centrifuged at 2000 x g for 15 min at 4°C, 
and plasma was transferred into fresh tubes. Tumour 
lysates were prepared as described previously [27]. For 
the quantitative determination of 17-β-estradiol, 
osteopontin (OPN), receptor activator for nuclear factor 
κB ligand (RANKL), osteocalcin and tartrate-resistant 
acid phosphatase 5b (TRACP5b), ELISA kits were used 
according to the manufacturers’ instructions (Demeditec 
Diagnostics GmbH, Germany; R&D Systems, Inc., 
Minneapolis, Canada; Elabscience, Houston, USA; and 
Cusabio, Houston, USA; respectively). 
 
 
 
 
Figure 2. The effect of calcitriol and its analogues on tumour progression in aged OVX mice. (A) Kinetics of tumour growth. 
(B) Tumour volume measured on the 21st day of the experiment. (C) Body weight kinetics. (D) Tumour blood perfusion estimated 
by ultrasound imaging as time to peak values measured on day 24 after 4T1 mammary gland inoculation. (E) Representative images 
of tumour perfusion in sham operated mice and OVX mice treated with vehicle or OVX mice treated with calcitriol (i) before and 
(ii) after contrast agent injection. (F) The number of mice diagnosed with metastases; graphs represent the number of mice with 
macroscopic metastatic nodules on days 14 and 21 (grey) and the number of mice in the group (N, blue). On the next days of 
observation in all animals, metastatic nodules were detected. (G) The number of lung metastases counted in fixed lungs on days 21, 
28 and 33. Mice were ovariectomized (OVX) or sham operated (Sham); after 4 weeks, they were inoculated orthotopically with 4T1 
cells (day 0). From day 7 (7 days after tumour inoculation), vitamin D analogues or vehicle were administered subcutaneously (s.c.) 
thrice weekly. The single doses of compounds were as follows: calcitriol, 0.5 µg/kg; PRI-2191, 1.0 µg/kg; and PRI-2205, 10.0 µg/kg. 
The number of mice analysed was 4-7 per group. Control mice (receiving the vehicle) are described as follows: "sham" - sham 
operated, tumour bearing mice; "control" - OVX, tumour bearing mice. Data presentation: (A) and (C) mean with standard deviation 
(SD); (B), (D) and (G) data for individual animals with mean and (SD). Statistical analysis: Kruskal–Wallis multiple comparison 
test. *P<0.05. 
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Figure 3. The influence of calcitriol and its analogues on bone mineralization in mice bearing 4T1 
tumours (day 0 and day 28). (A–E) Analysis performed on aged OVX mice. (F-I) Analysis performed 
on young mice. (A) and (F) Bone column density (corrected X-ray extinction for the cylindrical bone). (B) 
and (G) Marrow column density (corrected X-ray extinction for the marrow). (C) and (H) Bone density. 
(D) and (I) CaPO4 coefficient. (E) Representative X-ray pictures of aged OVX mice. Bruker In-Vivo FX 
PRO imaging equipped with an X-ray unit was used. Mice were ovariectomized (OVX) or sham operated 
(Sham), and after 4 weeks, they were inoculated orthotopically with 4T1 cells (day 0). From day 7 (7 days 
after tumour inoculation), vitamin D analogues or vehicle were administered subcutaneously (s.c.) thrice 
weekly. The single doses of compounds were as follows: calcitriol, 0.5 µg/kg; PRI-2191, 1.0 µg/kg; and 
PRI-2205, 10.0 µg/kg. Both femurs of 3-6 mice were used for analysis. Control mice (receiving the 
vehicle) are described as follows: "sham" - sham operated, tumour bearing mice; "control" - OVX, tumour 
bearing mice. Day 0 means mice not inoculated with cancer cells, sham-operated or OVX. Statistical 
analysis: Kruskal–Wallis multiple comparison test. *p<0.05 compared to control mice on the relevant day 
of treatment or as indicated.  
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Ex vivo assay for osteoclastogenesis 
 
To prepare bone marrow‐derived macrophages 
(BMDMs), bone marrow cells were collected from the 
tibiae and femurs of mice on day 28 of the experiment. 
After this, the cells were frozen in 90% foetal bovine 
serum (HyClone, GE Healthcare, UK) with 10% DMSO 
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany). 
Then, 10×106 thawed cells were seeded on the non-tissue 
culture-treated Petri dishes (Sarstedt, Numbrecht, 
Germany) in 10 ml of MEM-α (Thermo Scientific, 
Waltham, USA) containing 20 ng/ml M-CSF. Every other 
day, media were replaced with fresh media containing 20 
ng/ml M-CSF, and cultures were maintained for 7 days. 
Next, differentiated BMDMs were detached from dishes 
by trypsin, and 2×104 BMDMs were seeded in 24-well 
plates (Corning, New York, USA) in 500 µl of MEM-α 
supplemented with 20 ng/ml M-CSF and 20 ng/ml 
RANKL. Media were changed every other day, and 
cultures were maintained for 7 days. After this, the stain 
for active osteoclasts was prepared using an Acid 
Phosphatase Leukocyte (TRAP) Kit according to 
manufacturer’s instructions. Microscopic examination 
and photographs were captured using a bright field 
microscope (Olympus IX81) connected to a camera 
equipped with Olympus Stream Image Analysis software 
(Olympus Europe Holding GmBH, Hamburg, Germany). 
Blinded microscopic examination was performed at 10× 
magnification, and photographs were taken at 4× 
magnification. Characterized by stained acid phosphatase 
(dark purple colour visible in the cytoplasm of cells) and 
numerous cell nuclei (>5), active osteoclasts were counted 
over the entire surface of the well. The percentage of 
active osteoclasts in the study groups was compared to the 
values obtained for the control group.   
 
Statistical evaluation 
 
Statistical analysis was performed using GraphPad Prism 
7.01 (GraphPad Software Inc., USA). Shapiro–Wilk’s 
normality test and Bartlett’s test were used to check the 
assumptions for analysis of variance (ANOVA). Tests 
used for each data analysis are indicated in the figure 
legends. P < 0.05 was considered significant. 
 
RESULTS 
 
Calcitriol and its analogues transiently decreased the 
metastatic spread of 4T1 breast carcinoma without 
influencing primary tumour growth or angiogenesis in 
old OVX mice 
 
Initially, we evaluated whether calcitriol and selected 
analogues affected the growth of primary tumours and the 
degree of tumour vascularization in aged OVX mice. We 
measured the volume of the tumours and found that the 
examined compounds did not influence primary tumour 
growth at any of the times tested (Fig. 2A), with the 
exception of PRI-2205, which decreased tumour volume 
on day 21 (Fig. 2B). Accordingly, angiogenesis 
investigated by ultrasound imaging on day 24 was 
unaffected (Fig. 2D and E). 
Next, we analysed how many mice had macroscopic 
lung metastatic foci and found that 4 of 7 calcitriol-treated 
mice showed metastases after 14 days of treatment, 
whereas no metastases were detectable in control 4T1 
tumour bearing mice (Fig. 2F). On day 21, the number of 
mice with metastases was markedly higher in the groups 
treated with calcitriol and analogues than in the control 
groups (Fig. 2F). It is noteworthy that while the mean 
number of metastatic foci did not differ between the 
control and treated groups after day 21 (Fig. 2G), we 
observed a significant inhibition of lung colonization after 
28 days of treatment with PRI-2191 and PRI-2205. The 
influence on metastasis by calcitriol on day 28 was not 
statistically significant. At the end of the experiment (day 
33), the effect on lung metastasis was no longer observed 
(Fig. 2G). The tumour volume and number of metastases 
were lower in sham-operated mice than in control OVX 
mice (Fig. 2A, B and G). 
Calcitriol and analogues increased the tumour growth-
associated decrease in body weight 
Starting from day 23, the body weight of all mice 
decreased as a result of tumour progression. This effect 
was particularly evident in ovariectomized mice treated 
with calcitriol, PRI-2191 (p<0.05 starting from day 26) 
and PRI-2205 (Fig. 2C). Mice were sacrificed when their 
body weight decreased by more than 20% in the interval 
between two consecutive measurements or when mice 
showed clear symptoms of disease, such as changes in 
behaviour, posture, and appearance or tumours larger than 
2000 mm3 or with necrotic spots. In the control group, 1 
mouse was euthanized on day 26, and 3 were sacrificed 
on day 29. In the calcitriol-treated group, 2 mice were 
euthanized on day 30. In the group treated with PRI-2191, 
4 mice were euthanized on day 31. In the PRI-2205-
treated group, only 1 mouse was sacrificed on day 32. 
Both calcitriol analogues influenced bone 
mineralization in aged OVX mice  
 
PRI-2191 and PRI-2205, not calcitriol, decreased bone 
column density (Fig. 3A), marrow column density (Fig. 
3B) and the CaPO4 coefficient (Fig. 3D) in aged OVX 
mice, while they had no effect in young mice (Fig. 3F-I). 
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Figure 4. Ca2+ plasma concentration and vitamin D metabolites in the blood; plasma and tumour cytokine levels in aged 
OVX mice bearing 4T1 mammary gland tumours and treated with calcitriol and its analogues. (A) Plasma concentration 
of Ca2+. The amount of vitamin D metabolites in whole blood: (B) 25(OH)D3, (C) 24,25(OH)2D3, (D) 25(OH)D2. (E) 
Osteopontin (OPN) level in mouse plasma and (F) tumour tissue. Plasma concentration of (G) RANKL and (I) osteocalcin. 
Tumour tissue levels of (H) RANKL, (J) osteocalcin, (K) TRAC5b. Mice were ovariectomized (OVX) or sham operated 
(Sham); after 4 weeks, they were inoculated orthotopically with 4T1 cells (day 0). From day 7 (7 days after tumour inoculation), 
vitamin D analogues or vehicle were administered subcutaneously (s.c.) thrice weekly. The single doses of compounds were as 
follows: calcitriol, 0.5 µg/kg; PRI-2191, 1.0 µg/kg; and PRI-2205, 10.0 µg/kg. Number of samples analysed per group: 3-7. 
Control mice (receiving the vehicle) are described as follows: "sham" - sham operated, tumour bearing mice; "control" - OVX, 
tumour bearing mice. Day 0 means mice not inoculated with cancer cells, sham-operated or OVX. Statistical analysis: Kruskal–
Wallis multiple comparison test. *P<0.05 compared to control mice on the relevant day of treatment or as indicated.  
 
The calcium plasma concentration increased 
significantly after treatment with calcitriol (day 14) and 
PRI-2191 (day 28), whereas PRI-2205 diminished the 
Ca2+ level on day 21 (Fig. 4A). Vitamin D metabolites 
were also measured in mouse whole blood (Fig. 4B-D). 
Both calcitriol and PRI-2191 decreased the level of 
25(OH)D3 on days 14 (p<0.05) and 21 (Fig. 4B). During 
the course of the experiment, calcitriol and PRI-2191 
significantly decreased the blood level of 24,25(OH)2D3 
(Fig. 4C). Calcitriol also decreased the level of 25(OH)D2 
on days 21 and 28 (Fig. 4D). PRI-2205 did not 
significantly affect the level of plasma vitamin D 
metabolites (Fig. 4B-D).  
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Figure 5. Ex vivo osteoclastogenesis of bone marrow macrophages in aged OVX mice bearing 4T1 mammary gland tumours 
and treated with calcitriol or its analogues. (A) Active osteoclasts. TRAP-positive cells characterized by acid phosphatase staining 
(dark purple colour visible in the cytoplasm of cells) and more than five nuclei. BMDMs derived from mice on day 28 of the 
experiment were cultured with M‐CSF (20 ng/ml) and RANKL (20 ng/ml). Mice were ovariectomized (OVX) or sham operated 
(Sham); after 4 weeks, they were inoculated orthotopically with 4T1 cells (day 0). From day 7 (7 days after tumour inoculation), 
vitamin D analogues or vehicle were administered subcutaneously (s.c.) thrice weekly. The single doses of compounds were as 
follows: calcitriol, 0.5 µg/kg; PRI-2191, 1.0 µg/kg; and PRI-2205, 10.0 µg/kg. Data are presented as the mean and standard deviation 
(SD). The percentage of cells compared to control mice is presented. The number of samples analysed was 4 per group. "Control" 
means OVX, tumour bearing mice. Statistical analysis: Sidak’s multiple comparison test. *P<0.05 compared to control mice. (B) 
Representative microphotographs of TRAP-positive osteoclasts. Scale bar = 1 mm.  
Calcitriol and its analogues significantly decreased the 
level of OPN in the tumour tissue of aged OVX mice 
bearing 4T1 tumours. 
PRI-2205 significantly decreased the plasma level of 
OPN on days 14 and 28, and a similar trend was noted for 
PRI-2191, although it did not reach statistical significance 
(Fig. 4E). The analysis of cytokines in tumour tissue 
showed a marked decrease in OPN on day 33 by all 
compounds used (Fig. 4F). The concentrations of receptor 
activator of NF‐κB ligand (RANKL) and osteocalcin in 
mouse plasma were measured on days 21 and 28. On day 
21, treatment did not change the level of either protein 
(data not shown). A slight but not statistically significant 
increase in RANKL and osteocalcin levels was observed 
after 28 days of treatment with PRI-2191 (Fig. 4G and I, 
respectively). On day 21, RANKL showed a tendency 
(p=0.0623) to be increased in tumour tissue from mice 
treated with PRI-2191 (Fig. 4H). The osteocalcin tumour 
tissue level did not change significantly (Fig. 4J), but 
TRAC5b was significantly decreased by PRI-2191 (day 
28) (Fig. 4K). 
PRI-2191 and PRI-2205 increased the ex vivo 
differentiation of bone marrow macrophages to active 
osteoclasts in aged OVX mice 
 
The number of active osteoclasts generated from bone 
marrow-derived macrophages (BMDMs) was 
significantly increased in mice treated with both calcitriol 
analogues but not with calcitriol (Fig. 5A and B). 
  
Gene expression profile of tumour tissue harvested from 
aged OVX mice 
 
Tumour tissue specimens were collected on day 21 after 
the inoculation of 4T1 cells from mice treated with 
calcitriol or its analogues. The control group received only 
the vehicle for vitamin D compounds. Calcitriol or its 
analogues downregulated the expression of 4 genes 
related to the Th1 response in tumour tissue (Ifng (only 
calcitriol), Socs1, Tbx21 and Fasl) and upregulated 5 
genes related to the Th2 response (Ccl11, Ptgdr2, Il9, 
Asb2 and Il5). Ccl7 and Tmed, associated with the Th2 
response, were downregulated (Fig. 6, Supplemental 
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Table 2). The expression of two genes associated with 
Th17 cells is intriguing since the Il21 mRNA level 
decreased in tumour tissue from treated mice, whereas 
Il17re was increased. Seven genes related to Tregs were 
affected by treatment with calcitriol or its analogues; five 
of them were downregulated, i.e., Fosl, Gata4, Hopx, 
Lrrc32, and Tnfrsf9. Among the 2 upregulated genes, the 
most interesting was the increase in Tnfsf11 (RANKL) 
expression by PRI-2191 (fold-change 3.798) and PRI-
2205 (fold change 4.840) (Fig. 6, Supplemental Table 2). 
Moreover, the expression of Perp (TP53 apoptosis 
effector) was increased significantly in mice treated with 
calcitriol or its analogues, whereas Stat1, Stat4 and Stat6 
were downregulated by calcitriol and PRI-2191. 
 
 
Figure 6. Heat maps of tumour tissue real-time PCR screening performed using the Mouse T Helper Cell Differentiation RT2 
Profiler Array. Real-time PCR screening was performed using tumour tissue harvested on day 21. Data are presented as the mean 
fold change. The fold change (RQ) of target genes was defined using the double delta Ct method in reference to the heat shock protein 
90 alpha (cytosolic), class B member 1 (Hsp90ab1). The results were adjusted to the values obtained for the control group (OVX, 
tumour-bearing, vehicle treated). Data analysis was performed using Qiagen online software suitable for the purchased kits (Qiagen, 
Hilden, Germany). Each reaction contained 0.5 µg of cDNA (for each mouse in the group; 3 or 4 mice per group). 
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Figure 7. The main differences in the response to treatment with calcitriol and its analogues PRI-2191 and 
PRI-2205 between aged OVX and young mice bearing 4T1 breast cancer. Selected results of the analyses 
performed are presented. Young 6- to 8-week-old mice and aged 60-week-old ovariectomized (OVX) mice received 
an orthotopic injection of 4T1 mouse mammary gland cancer cells. Calcitriol (0.5 µg/kg), PRI-2191 (1 µg/kg) and 
PRI-2205 (10 µg/kg) were injected subcutaneously starting from day 7 and continuing three times a week to the end 
of the experiment. 
 
DISCUSSION 
 
The calcitriol analogues used in our studies were 
previously selected as low toxic analogues with anticancer 
activity in colon, mammary gland and lung cancer models 
[17,24,43–45]. However, in our recent studies, we have 
shown that calcitriol and these two low calcaemic 
analogues, PRI-2191 (tacalcitol) and PRI-2205, stimulate 
the lung metastasis of 4T1 mammary gland tumours 
growing in young mice. This undesirable effect is due to 
the induction of a cancer permissive milieu [27,28]. In this 
study, we highlight that the same scheme of treatment 
used in aged OVX mice has different effects on lung 
metastasis and tumour angiogenesis than those previously 
shown in young mice (Fig. 7). In aged OVX mice, we 
have shown a transient decrease in lung metastasis on day 
28 or a lack of pro-metastatic activity on day 33. This may 
result from the decrease in OPN expression and the lack 
of induction of angiogenesis in tumour tissue of these 
mice. Previously, in young mice, we have shown that 
tumour blood perfusion and tumour OPN level, as well as 
the Spp1 mRNA level in lung tissue, were stimulated by 
treatment with calcitriol and its analogues, and there was 
increased metastatic potential of 4T1 cells [27,28]. OPN 
is a known cytokine with pleiotropic action towards 
accelerating tumour growth, angiogenesis and metastasis 
[46–48]. It also acts by increasing the immunosuppressive 
properties of regulatory T cells (Tregs) in the metastatic 
niche [49]. Therefore, the reduction in the levels of this 
cytokine by calcitriol and its analogues in tumour tissue 
and by analogues in the plasma may be responsible for the 
decreased lung metastatic potential of 4T1 cells in old 
OVX mice. Reduced OPN levels in tumour tissue after the 
administration of calcitriol or its analogues were rather 
unexpected because the OPN gene (Spp1) contains a 
vitamin D response element (VDRE) in the promoter 
region, whereby calcitriol stimulates various cells to 
secrete OPN [50–52]. On the other hand, T and B 
lymphocytes secrete OPN only after activation [53], and 
calcitriol is known to decrease the number of activated T 
and B cells [54,55]. The downregulation of Stat1, Stat4 
and Stat6 observed in tumour tissue may confirm the 
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reduced response to cytokines of lymphocytes and 
therefore may indicate a decrease in lymphocyte 
activation. STAT1 is necessary for IFNγ signalling, and 
STAT1 and STAT4 (IL-12) are the main factors for Th1 
polarization. On the other hand, STAT6 stimulation by 
IL-4 is important for Th2 signalling [56–58]. Our gene 
expression analysis showed that many cytokines and their 
receptors were downregulated by calcitriol and its 
analogues in tumour tissue. 
OPN also plays a crucial role in bone remodelling 
since it is involved in osteoclast chemotaxis and 
attachment to bone, as well as in osteoclast generation and 
osteoblast function [59]. According to this, decreased 
plasma and tumour tissue OPN levels may be connected 
to the observed deterioration of some bone mineralization 
parameters in aged mice. Vitamin D prevents the 
demineralization of bone. However, it has also been 
demonstrated that calcitriol induces bone resorption. This 
activity is realized through RANKL, whose expression is 
stimulated by calcitriol in osteoblasts, thus inducing 
osteoclastogenesis via the NF-κB pathway [60]. In our 
studies, we show that in tumour tissue, the expression of 
the RANKL gene (Tnfsf11) was increased by both 
calcitriol analogues but not by calcitriol. This 
upregulation correlated with increased osteoclastogenesis 
of bone marrow-derived macrophages from the same 
mice, which explains the impaired bone mineralization. 
On the other hand, calcitriol or some calcitriol analogues 
such as eldecalcitol (1α,25-dihydroxy-2β-(3-
hydroxypropoxy) vitamin D3) or alfacalcidol (1α(OH)D3) 
are used in the treatment of osteoporosis because they 
increase bone mineralization by reducing bone resorption 
[61,62] through the suppression of RANKL expression in 
osteoblasts and decreased osteoclastogenic potential, as 
shown in eldecalcitol- or alfacalcidol-treated mice 
[63,64]. Moreover, Starczak et al. evaluated a conditional 
deletion mouse model, CtskCre/Vdr-/-, and showed that the 
absence of VDR in mature osteoclasts causes enhanced 
bone loss in young and OVX mice through increased 
osteoclastic activity without increased osteoclastogenesis 
[65]. Therefore, it has been shown that calcitriol itself and 
analogues such as eldecalcitol exert anti-osteoporotic 
activity through VDR.  
Our further studies, however, produced contradictory 
results. Whereas Tnfsf11 expression in tumour tissue was 
increased by the two calcitriol analogues, RANKL was 
not affected at the protein level in tumour tissue but was 
increased by PRI-2191 in the plasma (p=0.0889). PRI-
2191 also seemed to increase plasma osteocalcin levels 
(p=0.0933). This might suggest different 
posttranscriptional mechanisms in tumours compared to 
other tissues. Moreover, increased RANKL and 
osteocalcin and decreased OPN plasma concentrations 
suggest that calcitriol analogues induce intensive, 
ongoing bone remodelling in old OVX mice bearing 4T1 
breast cancer.  
PRI-2191 and PRI-2205 [66] have a higher binding 
affinity for vitamin D binding protein (DBP) than does 
calcitriol. However, PRI-2205 has a higher binding 
affinity for VDR than do calcitriol and PRI-2191 [66], 
whereas the affinity of PRI-2191 for VDR is similar to 
that of calcitriol [67]. We have previously shown that 
PRI-2205 possesses a higher binding affinity not only for 
VDR and DBP but also for the CAR/RXR (constitutive 
androstane receptor/retinoid X receptor) ligand binding 
domain. This may, in part, explain its very low toxicity 
and sustained anticancer activity [68], as well as the 
different mechanisms of action in comparison to PRI-
2191 and calcitriol [39,66,68]. It may also explain why 
PRI-2205 did not affect vitamin D metabolite levels, as 
shown in our recent studies, whereas calcitriol and PRI-
2191 decreased the levels of 25(OH)D3 and 
24,25(OH)2D3 in aged OVX mice. Calcitriol and PRI-
2191 are metabolized to inactive metabolites through 
CYP24 [69], a target of VDR [70]. The transactivation of 
responsive elements in CYP24 by the VDR/RXR 
complex leads to increased expression of CYP24 and 
reduced levels of the biologically active calcitriol [70]. 
Moreau et al. showed that CAR binds and transactivates 
VDREs present in the CYP24 promoter. They also 
established that a specific human CAR agonist, CITCO, 
increases CYP24 mRNA expression in primary human 
hepatocytes. These findings suggest that VDR-CAR 
crosstalk resulting from the recognition of the same 
response elements is reciprocal [70]. Such crosstalk 
provides, at least in part, an explanation for the observed 
differences in the levels of vitamin D metabolites, which 
are similar in calcitriol- and PRI-2191-treated mice but 
different in PRI-2205-treated mice. However, studies 
have shown that calcipotriol (with the same side chain 
modification as PRI-2205) may share catabolic enzymes 
with calcitriol [71]. On the other hand, the affinity of 
calcipotriol for VDR is similar to that of calcitriol, but it 
is 30-fold lower for DBP [72]. Therefore, we can 
speculate that the highest DBP, VDR and CAR/RXR 
binding among all tested compounds may alter the 
metabolic pathway of PRI-2205.  
Up to the present, young mice inoculated with various 
tumour cells were commonly used as an in vivo model for 
structure–activity studies of vitamin D3 analogues as 
potential anticancer agents. It is worth emphasizing that 
when we measured plasma levels of 25(OH)D in young 
4T1 tumour bearing mice, both calcitriol and PRI-2191 
decreased their levels (similar to what was observed in the 
current study), but PRI-2205 revealed similar activity [27] 
that was not observed in OVX mice. These results indicate 
that the profile of activities of calcitriol and its analogues 
differ based on age. In Figure 7, we summarize the 
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differences detected during our studies between young 
[27,28] and aged OVX mice bearing 4T1 tumours. In 
conclusion, in-depth metabolic pathway studies, as well 
as studies on anticancer activity and analyses of bone 
metabolism in old mouse models, are needed before 
considering new vitamin D analogues with various 
chemical modifications as effective drugs supporting 
anticancer treatment, especially in the elderly.  
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